(Q34737478)

4 August 2017

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis (English)

1 reference

4 August 2017

0 references

Raed Alroughani

35

0 references

Tomáš Kalinčík

Tomas Kalincik

1

0 references

Thor Petersen

Thor Petersen

19

0 references

Helmut Butzkueven

Helmut Butzkueven

51

0 references

Mark Slee

Mark Slee

33

0 references

Alessandra Lugaresi

Alessandra Lugaresi

7

0 references

Maria Trojano

Maria Trojano

3

0 references

Maria Pia Amato

Maria Pia Amato

18

0 references

Roberto Bergamaschi

21

Roberto Bergamaschi

1 reference

4 August 2017

49

Steve Vucic

1 reference

4 August 2017

5

Guillermo Izquierdo

1 reference

4 August 2017

4

Pierre Duquette

1 reference

Jose Antonio Cabrera-Gomez

4 August 2017

50

Jose Antonio Cabrera-Gomez

1 reference

4 August 2017

23

Cavit Boz

1 reference

4 August 2017

22

Gerardo Iuliano

1 reference

4 August 2017

Francois Grand-Maison

11

Francois Grand'maison

1 reference

4 August 2017

8

Raymond Hupperts

1 reference

4 August 2017

10

Vincent Van Pesch

1 reference

4 August 2017

Jeannette Lechner-Scott

24

Jeannette Lechner-Scott

1 reference

4 August 2017

28

Marcela Fiol

1 reference

4 August 2017

15

Celia Oreja-Guevara

1 reference

4 August 2017

34

Maria Laura Saladino

1 reference

4 August 2017

27

Freek Verheul

1 reference

4 August 2017

9

Edgardo Cristiano

1 reference

4 August 2017

Daniele L A Spitaleri

12

Daniele La Spitaleri

1 reference

4 August 2017

13

Maria Edite Rio

1 reference

4 August 2017

14

Sholmo Flechter

1 reference

4 August 2017

17

Aldo Savino

1 reference

Ricardo Fernandez-Bolanos

4 August 2017

20

Ricardo Fernandez-Bolanos

1 reference

4 August 2017

25

Norma Deri

1 reference

4 August 2017

26

Orla Gray

1 reference

4 August 2017

31

Vetere Santiago

1 reference

4 August 2017

32

Fraser Moore

1 reference

4 August 2017

37

Krisztian Kasa

1 reference

Tatjana Petkovska-Boskova

4 August 2017

38

Tatjana Petkovska-Boskova

1 reference

4 August 2017

41

Eli Skromne

1 reference

4 August 2017

43

Dieter Poehlau

1 reference

4 August 2017

Walter Oleschko Arruda

46

Walter Oleschko Arruda

1 reference

4 August 2017

Mark John Ingraham Paine

47

Mark Paine

1 reference

4 August 2017

52

MSBase Study Group

1 reference

4 August 2017

6

Pierre Grammond

1 reference

4 August 2017

29

Michael Barnett

1 reference

4 August 2017

Timothy Spelman

2

1 reference

4 August 2017

Giorgio Giuliani

16

1 reference

4 August 2017

Erik van Munster

30

1 reference

4 August 2017

Cameron Shaw

36

1 reference

4 August 2017

Leontien den Braber-Moerland

39

1 reference

4 August 2017

Joab Chapman

40

1 reference

4 August 2017

Joseph Herbert

42

1 reference

4 August 2017

Merrilee Needham

44

1 reference

4 August 2017

Elizabeth Alejandra Bacile Bacile

45

1 reference

4 August 2017

Bhim Singhal

48

1 reference

4 August 2017

language of work or name

English

0 references

publication date

21 May 2013

1 reference

4 August 2017

1 reference

4 August 2017

8

1 reference

4 August 2017

e63480

1 reference

4 August 2017

5

1 reference

Creative Commons Attribution 4.0 International

4 August 2017

start time

21 May 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3660604

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3660604

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3660604

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3660604

Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3660604

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3660604

observational studies: propensity score analysis of non-randomized data.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3660604

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3660604

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3660604

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

7 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063480

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063480

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063480

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063480

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

21 January 2018

1 reference

12 December 2020

The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis

1 reference

12 December 2020

New natural history of interferon-β-treated relapsing multiple sclerosis

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0063480

Identifiers

DOI

1 reference

4 August 2017

0 references

1 reference

4 August 2017

1 reference